From: Nanomedicine review: clinical developments in liposomal applications
References | Disease | LF | Toxicity Grade 3–5 (%) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hematological | Non-hematological | ||||||||||||
N | T | L | A | F | Na | D | V | S/M | HFS | R | |||
Banerjee et al. (2018) | ROC | PLD | 4 | 6 | 2 | 6 | 6 | ||||||
Lee et al. (2017) | ROC | PLD | 7 | 3 | 4 | ||||||||
Monk et al. (2017)a | ROC | PLD | 74.1 | 33.3 | 4.1 | ||||||||
Marth et al. (2017) | ROC | PLD | 15 | 4 | 5 | 5 | 5 | 6 | 6 | 12 | 2 | ||
Lindemann et al. (2017) | ROC | PLD | 2 | 2 | 7 | 7 | |||||||
Herzog et al. (2016) | ROC | PLD | 13 | 13 | |||||||||
Runnebaum et al. (2018) | ROC | PLD + trebananib | 18 | 10 | 15 | 5 | 5 | ||||||
Lee et al. (2017) | ROC | PLD + carboplatin | 26 | 13 | 8 | ||||||||
Sehouli et al. (2016) | ROC | PLD + carboplatin | 27 | 15 | 17 | 10 | 2 | 2 | |||||
Nagao et al. (2016) | ROC | PLD + paclitaxel + carboplatin | 83 | 33 | 83 | 100 | 17 | 50 | 17 | ||||
Landrum et al. (2016) | ROC | PLD + carboplatin + bevacizumab + veliparib | 30 | 40 | 30 | ||||||||
Kim et al. (2015) | ROC | PLD + carboplatin + farletuzumab | 40 | 13 | 67 | 33 | 20 | 20 | 33 | 33 | |||
Monk et al. (2017)a | ROC | PLD + motolimod | 87.8 | 50.3 | 10.9 | ||||||||
Marth et al. (2017) | ROC | PLD + trebananib | 8 | 4 | 7 | 6 | 3 | 6 | 7 | 20 | 2 | ||
Shoji et al. (2017) | ROC | PLD + irinotecan | 55 | 3 | 32 | 10 | 3 | 3 | 3 | 10 | |||
Thaker et al. (2017) | ROC | PLD + GEN | 71 | 57 | 28 | 28 | |||||||
Herzog et al. (2016) | ROC | PLD + vintafolide | 17 | 5 | 5 | ||||||||
Jehn et al. (2016) | MBC | Caelix® | 4 | 12 | |||||||||
Harbeck et al. (2016) | MBC | PLD | 3 | 1 | 4 | 1 | 4 | 6 | 39 | ||||
Chang et al. (2018) | MBC | PLD + cyclophosphamide | 42 | 47 | 5 | 10 | 5 | 1 | |||||
Tampaki et al. (2018) | BC | PLD + cyclophosphamide + bevacizumab + paclitaxel | 24 | 1.6 | 6.5 | 1.6 | 9.7 | ||||||
Basho et al. (2016) | TNBC | PLD + bevacizumab + temsirolimus | 8 | 4 | 4 | 8 | 13 | ||||||
PLD + bevacizumab + everolimus | 22 | 11 | 22 | 22 | 11 | ||||||||
Rocca et al. (2017) | BC | PLD + lapatinib | 11 | 11 | 11 | ||||||||
Coltelli et al. (2017) | BC | Myocet® + cyclophosphamide + PTX | 25 | 6 | 4 | 6 | |||||||
Cohen et al. (2018) | MM | PLD + pomalidomide + dexamethasone | 51 | 4 | 38 | 31 | 9 | ||||||
Orlowski et al. (2016) | RMM | PLD + bortezomib | |||||||||||
Becker et al. (2016) | MM | PLD + bortezomib + cyclophosphamide + dexamethasone | 10 | 5 | 5 | 5 | 10 | ||||||
Voorhees et al. (2017) | RMM | PLD + bortezomib + vorinostat | 37 | 47 | 16 | 9 | 19 | 9 | 9 | ||||
Luminari et al. (2017) | DLBCL | Myocet® + cyclophosphamide + vincristine + prednisone | 64 | 8 | 46 | 2 | |||||||
Fridrik et al. (2016) | DLBCL | Myocet® + cyclophosphamide + vincristine + prednisone + rituximab | 50 | 50 | 85 | 29 |